Value of CTS5 for Late Relapse Risk Assessment in Patients with Early Stage HER2+ Breast Cancer in the NCCTG N9831 (Alliance) Trial
- Citation:
- J Clin Oncol vol 38 (15_suppl) 529
- Meeting Instance:
- ASCO 2020
- Year:
- 2020
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 3906
- Pharmas:
- Genentech
- Grants:
- U10CA180821 , U10CA180882;
- Corr. Author:
- Authors:
- Tanmayi Pai Angelica Gil Yaohua Ma Zhuo Li Pooja Advani Alvaro Moreno-Aspitia Gerardo Colon-Otero Edith A. Perez E.A. Thompson Saranya Chumsri
- Networks:
- LAPS-MN026, NY021, PR028
- Study
- NCCTG-N9831
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: